XML 47 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:      
Net loss $ (5,507) $ (4,250) $ (10,892)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation expense 109 111 74
Stock-based compensation 588 492 625
Amortization of premium on short-term investments 79 132  
Other 17    
Non-cash interest income   (16)  
Realized gain on sale of short-term investments     (46)
Change in fair value of investor stock purchase option     2,290
Changes in operating assets and liabilities:      
Accounts receivable 9 16 (56)
Inventories (23) (286) (606)
Prepaid expenses and other current assets (3) 1,160 (1,223)
Accounts payable 248 (95) 96
Accrued liabilities 280 (368) 355
Accrued milestone and royalties   (5,001) 5,005
Net cash used in operating activities (4,203) (8,105) (4,378)
Cash flows from investing activities:      
Proceeds from sales and maturities of short-term investments 6,459 4,029 966
Purchases of short-term investments (4,526) (6,869) (241)
Purchase of property and equipment (117) (112) (254)
Proceeds from sale of property and equipment 2    
Net cash provided by (used in) investing activities 1,818 (2,952) 471
Cash flows from financing activities:      
Proceeds from sale of common stock in a public offering, net of issuance costs of $1,059 5,441    
Proceeds from sale of common stock under common stock purchase agreement, net of related costs of $4 135    
Proceeds from sale of common stock in IPO, net of issuance costs of $2,868   13,632  
Proceeds from exercise of investor option to purchase common stock     3,750
Proceeds from sale of common stock under private placement offerings, net of issuance costs     1,236
Proceeds from the exercise of employee stock options 1 88  
Net cash provided by financing activities 5,577 13,720 4,986
Net increase in cash and cash equivalents 3,192 2,663 1,079
Cash and cash equivalents at beginning of period 6,211 3,548 2,469
Cash and cash equivalents at end of period 9,403 6,211 3,548
Supplemental disclosures:      
Interest paid in cash     1
Supplemental non-cash disclosures:      
Reclassification of investor stock purchase option liability to equity     $ 3,250